InvestLog
CGEM Cullinan Therapeutics, Inc. logo

CGEM Cullinan Therapeutics, Inc.

Healthcare
$13.84-1.00%ClosedMarket Cap: $850.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.24

P/S

0.00

EV/EBITDA

-3.31

DCF Value

$1.44

FCF Yield

-21.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-51.5%

ROA

-54.9%

ROIC

-65.2%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-49.7M$—
Q4 null$0.00$-50.7M$—
FY null$0.00$-219.9M$—
Q3 null$0.00$-50.6M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$31.00

Target (Median)

$30.00

Target Range

$28.00 - $37.00

1 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell
BTIGBuy
2026-05-19
WedbushOutperform
2026-05-08
HC Wainwright & Co.Buy
2026-04-28
WedbushOutperform
2026-03-11
HC Wainwright & Co.Buy
2026-01-08

Trading Activity

Insider Trades

View All
Michaelson Jenniferofficer: Chief Scientific Officer
SellWed May 06
Michaelson Jenniferofficer: Chief Scientific Officer
SellWed May 06
Michaelson Jenniferofficer: Chief Scientific Officer
SellWed May 06
Michaelson Jenniferofficer: Chief Scientific Officer
SellMon Mar 09
Michaelson Jenniferofficer: Chief Scientific Officer
SellMon Mar 09

Company Info

Sector

Healthcare

Industry

Medical - Pharmaceuticals

Country

US

Exchange

—

Beta

-0.09

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Peers

ADCT logoADCTBCYC logoBCYCCBLL logoCBLLEHAB logoEHABLAB logoLABNMRA logoNMRAOMER logoOMERRAPT logoRAPTSY logoSYVREX logoVREX